CN112933201A - Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating diabetic nephropathy and preparation method thereof - Google Patents
Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating diabetic nephropathy and preparation method thereof Download PDFInfo
- Publication number
- CN112933201A CN112933201A CN202110318766.4A CN202110318766A CN112933201A CN 112933201 A CN112933201 A CN 112933201A CN 202110318766 A CN202110318766 A CN 202110318766A CN 112933201 A CN112933201 A CN 112933201A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- prepared
- diabetic nephropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 44
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 16
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 15
- 235000006533 astragalus Nutrition 0.000 claims abstract description 15
- 241000759833 Cornus officinalis Species 0.000 claims abstract description 14
- 235000002566 Capsicum Nutrition 0.000 claims abstract description 12
- 239000006002 Pepper Substances 0.000 claims abstract description 12
- 235000016761 Piper aduncum Nutrition 0.000 claims abstract description 12
- 235000017804 Piper guineense Nutrition 0.000 claims abstract description 12
- 235000008184 Piper nigrum Nutrition 0.000 claims abstract description 12
- 241000218989 Trichosanthes Species 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 241000382455 Angelica sinensis Species 0.000 claims description 15
- 241000045403 Astragalus propinquus Species 0.000 claims description 13
- 241001506371 Kadsura Species 0.000 claims description 11
- 241000722363 Piper Species 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 6
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 41
- 239000008280 blood Substances 0.000 abstract description 41
- 210000003734 kidney Anatomy 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 18
- 210000002700 urine Anatomy 0.000 abstract description 14
- 244000164480 Curcuma aromatica Species 0.000 abstract description 13
- 235000014375 Curcuma Nutrition 0.000 abstract description 12
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract description 12
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract description 12
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract description 12
- 235000019509 white turmeric Nutrition 0.000 abstract description 12
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 241000908494 Dioscorea nipponica Species 0.000 abstract description 8
- 235000017008 Dioscorea nipponica Nutrition 0.000 abstract description 8
- 229940109239 creatinine Drugs 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 241000721047 Danaus plexippus Species 0.000 abstract description 3
- 241001061264 Astragalus Species 0.000 abstract description 2
- 230000003014 reinforcing effect Effects 0.000 abstract description 2
- 210000004233 talus Anatomy 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241001506304 Kadsura japonica Species 0.000 abstract 1
- 244000203593 Piper nigrum Species 0.000 abstract 1
- 241000218206 Ranunculus Species 0.000 abstract 1
- 238000007599 discharging Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 24
- 238000001914 filtration Methods 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 230000001603 reducing effect Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 201000001474 proteinuria Diseases 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 208000020832 chronic kidney disease Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000008517 radix Trichosanthis Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 239000005541 ACE inhibitor Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000172774 Ranunculus ternatus Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 241000209020 Cornus Species 0.000 description 2
- 241000963390 Curcuma wenyujin Species 0.000 description 2
- 235000003394 Curcuma wenyujin Nutrition 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 240000009022 Smilax rotundifolia Species 0.000 description 2
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 240000006023 Trichosanthes kirilowii Species 0.000 description 2
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000020905 low-protein-diet Nutrition 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- YSTPAHQEHQSRJD-UHFFFAOYSA-N 3-Carvomenthenone Chemical compound CC(C)C1CCC(C)=CC1=O YSTPAHQEHQSRJD-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000266855 Astragalus mongholicus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000142975 Cornaceae Species 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 235000003398 Curcuma aromatica Nutrition 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 241000729196 Lycopus lucidus Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 244000111261 Mucuna pruriens Species 0.000 description 1
- 235000006161 Mucuna pruriens Nutrition 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000534014 Piper kadsura Species 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 241000208966 Polygala Species 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 241001063882 Smilax moranensis Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000975594 Trichosanthes rosthornii Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 208000011279 abdominal lump Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229960003345 empagliflozin Drugs 0.000 description 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940082094 irbesartan 150 mg Drugs 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229930006968 piperitone Natural products 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- -1 qi-tonifying Chemical class 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for treating diabetic nephropathy, which comprises 5-30 parts of raw astragalus, 5-20 parts of codonopsis pilosula, 5-20 parts of prepared cornus officinalis, 5-20 parts of herba lycopi, 5-20 parts of rhizoma alismatis, 5-30 parts of ternate buttercup root, 10-40 parts of rhizoma smilacis glabrae, 5-20 parts of kadsura pepper stem, 5-20 parts of dioscorea nipponica, 5-20 parts of trichosanthes root, 5-20 parts of angelica and 5-20 parts of curcuma zedoary. The invention also provides a traditional Chinese medicine preparation prepared from the traditional Chinese medicine composition and a preparation method thereof. The traditional Chinese medicine composition has complete monarch, minister, assistant and guide functions, precise compatibility and mutual assistance, has the functions of reinforcing the kidney, dispelling wind, discharging turbidity and dredging collaterals, has obvious effect on improving the clinical symptoms of diabetic nephropathy, can reduce the blood creatinine, urea nitrogen and urine protein of patients with diabetic nephropathy, has good kidney protection effect and has good application prospect.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a traditional Chinese medicine composition for treating diabetic nephropathy, a traditional Chinese medicine preparation and a preparation method thereof.
Background
Diabetic Nephropathy (DN) is a common chronic complication of type 1 and type 2 diabetes mellitus, is clinically mainly manifested by chronic hyperglycemia, proteinuria and progressive renal function impairment, and has a high disability rate. The pathogenesis of diabetic nephropathy is not clarified, and genetic factors, hemodynamic changes, inflammatory cell infiltration, glucose metabolism disorders and hypoxia are considered to cause diabetic nephropathy. In recent years, the incidence of diabetic nephropathy in China is increasing, and the diabetic nephropathy is the main cause of end-stage nephropathy at present, and is second to glomerulonephritis. The chronic kidney disease can cause cardiovascular events, the medical cost of the chronic kidney disease is 1.8 times of that of the non-chronic kidney disease, and a heavy economic burden is caused to the individual and the society of the patient.
At present, no specific treatment method for diabetic nephropathy exists, the main principles of treatment are blood sugar, blood pressure and blood fat control and proteinuria reduction, and no effective means is available for preventing DN disease progression. Currently, Angiotensin Converting Enzyme Inhibitors (ACEIs) or angiotensin receptor Antagonists (ARBs) are the first choice for treating DN, and new studies have shown that Mineralocorticoid Receptor Blockers (MRBs) in combination with ACEIs or ARBs can help to reduce proteinuria. Novel hypoglycemic agents, such as sodium-glucose cotransporter 2(SGLT2) inhibitors, such as empagliflozin and dapagliflozin, can reduce proteinuria and reduce the occurrence of complex renal outcomes. GLP-1 agonists also have a beneficial effect on proteinuria, and liraglutide can reduce the dose-dependence of proteinuria. However, the above treatments still have limitations and adverse reactions, and a more effective treatment for DN needs to be found.
The pathogenesis of diabetes is based on yin deficiency, and excessive dryness-heat, so ancient people mostly adopt syndrome differentiation and treatment of upper, middle and lower digestions. The differentiation and classification of diabetic nephropathy and the treatment of diabetic nephropathy are not unified, and modern researches show that part of single medicines and extracts thereof such as astragalus, polygonatum polysaccharides, berberine and the like can delay the progress of diabetic nephropathy, and traditional Chinese medicine compound such as qi-tonifying, detoxifying, blood stasis-removing small compound traditional Chinese medicine, Jisheng kidney qi pills, kidney-eliminating decoction and the like can delay the progress of diabetic nephropathy through different mechanisms. However, the Chinese patent medicines on the market such as diabetes pill, Yuquan pill, etc. all focus on nourishing yin and clearing heat, tonifying qi and promoting the production of body fluid, have poor pertinence to the symptoms related to diabetic nephropathy, and the curative effect needs to be further improved.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, provides the traditional Chinese medicine composition for treating diabetic nephropathy and the traditional Chinese medicine preparation prepared by adopting the traditional Chinese medicine composition, obviously improves the clinical symptoms of the diabetic nephropathy, reduces the serum creatinine, the urea nitrogen and the urine protein of a diabetic nephropathy patient, and has good kidney protection effect.
The invention provides a traditional Chinese medicine composition for treating diabetic nephropathy, which is prepared from the following traditional Chinese medicines in parts by weight: 5-30 parts of raw astragalus membranaceus, 5-20 parts of codonopsis pilosula, 5-20 parts of cornus officinalis, 5-20 parts of herba lycopi, 5-20 parts of rhizoma alismatis, 5-30 parts of radix ranunculi ternati, 10-40 parts of rhizoma smilacis glabrae, 5-20 parts of kadsura pepper stem, 5-20 parts of rhizoma dioscoreae nipponicae, 5-20 parts of trichosanthes root, 5-20 parts of angelica sinensis and 5-20 parts of curcuma zedoary.
The traditional Chinese medicine composition is prepared from the following traditional Chinese medicines in parts by weight: 15-30 parts of raw astragalus membranaceus, 10-20 parts of codonopsis pilosula, 8-20 parts of prepared cornus officinalis, 8-20 parts of herba lycopi, 5-20 parts of rhizoma alismatis, 15-30 parts of radix ranunculi ternati, 20-40 parts of rhizoma smilacis glabrae, 8-20 parts of kadsura pepper stem, 10-20 parts of rhizoma dioscoreae nipponicae, 10-20 parts of trichosanthes root, 8-20 parts of angelica sinensis and 8-20 parts of curcuma zedoary.
The traditional Chinese medicine composition is prepared from the following traditional Chinese medicines in parts by weight: 30 parts of raw astragalus membranaceus, 15 parts of codonopsis pilosula, 10 parts of cornus officinalis, 12 parts of herba lycopi, 10 parts of rhizoma alismatis, 30 parts of radix ranunculi ternati, 40 parts of rhizoma smilacis glabrae, 12 parts of kadsura pepper stem, 15 parts of dioscorea nipponica, 15 parts of trichosanthes root, 12 parts of angelica sinensis and 10 parts of curcuma zedoary.
The preparation method of the traditional Chinese medicine composition comprises the following steps: extracting with water, and making into final product.
The specific water extraction method comprises the following steps: taking the traditional Chinese medicine raw materials, adding 8-16 times (by weight) of water, decocting for 1 hour, filtering, and preparing the filtrate for later use; adding 8-16 times (by weight) of water into the filter residue, decocting for 1 hr, filtering, discarding the filter residue, mixing the previous filtrates, concentrating, drying, and making into pill, tablet, capsule, liquid, etc.
The traditional Chinese medicine composition is prepared into a traditional Chinese medicine preparation by adding pharmaceutically acceptable auxiliary materials after extracting traditional Chinese medicine raw materials, and the preparation form is one of pills, tablets, capsules, granules, soft capsules and oral liquid.
The traditional Chinese medicine composition is applied to preparing a medicine for treating diabetic nephropathy.
Radix astragali is dried root of Astragalus mongholicus (Astragalus mongholicus Bunge) belonging to Leguminosae. Mainly produced in inner Mongolia, Shanxi and Heilongjiang provinces of China. Radix astragali is warm in nature, and has effects of invigorating qi, invigorating yang, consolidating superficial resistance, arresting sweating, and promoting granulation. It can be used for treating deficiency of qi and blood, spontaneous perspiration, chronic diarrhea, proctoptosis, metroptosis, nephritis, edema, albuminuria, diabetes, and chronic ulcer. Recent researches show that the extract astragaloside IV has the effects of enhancing immune system, resisting oxidation, delaying aging, improving cardiac function, resisting virus, resisting cancer and the like.
Radix Codonopsis is in Codonopsis of Campanulaceae (Codonopsis pilosula (Franch.) Nannf.), and produced in North China at 1560 + 3100 m mountain forest edge and bush. Has neutral nature and sweet taste, has the effects of invigorating spleen and replenishing qi, quenching thirst, strengthening spleen and benefiting lung, nourishing blood and promoting fluid production, and is mainly used for treating weakness of spleen and stomach, deficiency of both qi and blood, tiredness and weakness, anorexia, thirst, long-term diarrhea and rectocele. Recent researches show that the main component polysaccharide has the effects of enhancing the immunity of organisms, resisting aging, reducing blood sugar and the like.
Fructus Corni is prepared by steaming fructus Corni (Cornus officinalis Sieb. et Zucc.) of Cornaceae, removing inner core, drying in the sun, and is distributed in Shanxi, Jiangsu, Zhejiang, Anhui, Jiangxi, Shandong, Henan, Hunan, Sichuan, Shaanxi, Gansu, etc. Sour, astringent and slightly warm, entering liver and kidney meridians. Has the efficacies of tonifying liver and kidney, astringing and relieving depletion. It is commonly used for vertigo, tinnitus, soreness and pain of waist and knees, impotence, spermatorrhea, enuresis, frequent micturition, metrorrhagia, leukorrhagia, profuse sweating, exhaustion, internal heat, and diabetes. Modern medical research shows that the dogwood has the functions of enhancing the immune system, resisting inflammation, inhibiting bacteria, reducing blood sugar, resisting shock, resisting oxidation, resisting tumors and the like.
Herba Lycopi is dried aerial part of Polygala hirsuta seedling (Lycopus lucidus Turcz. vat. hirtus Regel) belonging to Labiatae. Is distributed in most areas of China. Bitter and pungent with mild warm nature. It enters liver and spleen meridians. Has the effects of activating blood circulation, regulating meridians, removing blood stasis, eliminating carbuncle, inducing diuresis and relieving swelling. Can be used for treating menoxenia, amenorrhea, dysmenorrhea, puerperal blood stasis and abdominal pain, skin ulcer, carbuncle, toxic swelling, edema, and ascites. Modern researches show that herba lycopi can improve renal interstitial fibrosis and delay the progress of chronic renal diseases by promoting the expression of HGF and VEGF.
Alismatis rhizoma is dried tuber of Alismatis rhizoma (Alisma orientalis (Sam.) Juzep.) of Alismaceae. Sweet and cold in nature. Entering kidney and bladder meridians, promoting urination, clearing away damp-heat, and treating dysuria, edema, distention, diarrhea, oliguria, phlegm-fluid dizziness, and stranguria with astringency and pain. Modern researches show that the rhizoma alismatis water extract can obviously inhibit the formation of experimental kidney stones of rats induced by glycol and active vitamin D3.
Ranunculus ternatus (Thunb.) nakai is dried root tuber of Ranunculus ternatus (Ranunculus ternatus Thunb.) nakai of Ranunculaceae. Is distributed in Guangxi, Taiwan, Jiangsu, Zhejiang, Jiangxi, Hunan, Anhui, Hubei, Henan, etc. Sweet and pungent in flavor and warm in nature. It enters liver and lung meridians. Has the effects of reducing phlegm and resolving masses, and detoxifying and reducing swelling. It is commonly used for scrofula, subcutaneous nodule, furuncle, pyogenic infections, snake and insect bite. Modern researches show that the compound radix ranunculi ternati aqueous extract has anti-inflammatory effect.
Rhizoma Smilacis Glabrae is dried Rhizome of Smilax scobinicaulis (Glabrous Greenbrier Rhizome) of Liliaceae. Sweet and light taste, mild nature, and has the effects of removing toxic substances, eliminating dampness, and benefiting joints. It can be used for treating syphilis, stranguria with turbid urine, spasm and pain of tendons and bones, tinea pedis, furuncle, carbuncle, swelling, and lymphoid tuberculosis. Modern researches show that the glabrous greenbrier rhizome has better immunity and anti-inflammatory efficacy.
Caulis Piperis Futokadsurae is dry stem of caulis Sinomenii (Piper kadsura (Choisy)0hwi) of Piperaceae, is pungent and bitter in taste, slightly warm in nature, and enters liver meridian. Has the effects of dispelling wind-damp, dredging channels and collaterals, and relieving arthralgia, and can be used for treating anemofrigid-damp arthralgia, limb joint pain, spasm of tendons and vessels, and difficulty in flexion and extension. The effective component piperitone has antiinflammatory effect, and the futenone can antagonize human neutrophil aggregation and degranulation reaction caused by platelet activating factor, and can block rat skin vascular permeability enhancing reaction caused by activating factor, histamine, and bradykinin
Ningpo Yam rhizome, the dried rhizome of Dioscorea nipponica Makino, is mainly distributed in Liaoning, Jilin, Heilongjiang, Hebei, inner Mongolia and other places. Sweet and bitter in flavor, warm in nature, entering liver, kidney and lung meridians. Has effects in expelling pathogenic wind, removing dampness, relaxing muscles and tendons, expelling collateral obstruction, promoting blood circulation, relieving pain, and relieving cough and asthma, and can be used for treating rheumatism, numbness of joints, traumatic injury, lumbar sprain, and cough and asthma. The research shows that the effective component total saponin can obviously reduce rabbit blood cholesterol and blood pressure, delay heart rate, strengthen heart contraction amplitude, increase urine volume, reduce beta/alpha lipoprotein ratio and improve coronary circulation.
Trichosanthis radix is dry root of Trichosanthes kirilowii Maxim or Trichosanthes rosthornii Maxim of Cucurbitaceae. Distributed in Henan et al. Sweet, slightly bitter and slightly cold in taste, enters lung and stomach channels, has the efficacies of clearing heat and purging fire, promoting fluid production to quench thirst, and reducing swelling and expelling pus, and is mainly used for treating fever polydipsia, lung heat dry cough, internal heat diabetes, sore and ulcer pyogenic infections. The research shows that 5 glycan components separated from trichosanthes root can reduce the blood sugar of mice.
Angelica sinensis (Oliv.) Diels is dried root of Angelica sinensis (Oliv.) Diels) belonging to family Umbelliferae. The major production in southeast Gansu province has high yield and good quality in Min county, and is provinces such as Yunnan, Sichuan, Shaanxi, Hubei and the like. Sweet and pungent in flavor, warm in nature, entering liver, heart and spleen meridians. Has the functions of enriching blood, promoting blood circulation, regulating menstruation, relieving pain, moistening intestine and relaxing bowels. It is commonly used for blood deficiency and sallow complexion, vertigo and palpitation, irregular menstruation, amenorrhea and dysmenorrhea, deficiency cold and abdominal pain, rheumatic arthralgia, traumatic injury, carbuncle, ulcer, constipation due to intestinal dryness. The wine angelica sinensis can activate blood and promote menstruation. Can be used for treating amenorrhea, dysmenorrhea, rheumatalgia, and traumatic injury. The effective component ferulic acid has blood lipid reducing effect.
Zedoary, the root and stem of Curcuma zedoary (Curcuma aromatica Roxb. [ c.zedoaria non Rosc. ]), Guangxi Curcuma zedoary (Curcuma kwangsisensis S.G.Lee et C.F.Liang) and Curcuma wenyujin Y.H.Chen et C.Ling) of the zingiberaceae family, are distributed in Guangdong, Guangxi, Sichuan, Yunnan, etc.; pungent and bitter in flavor, warm in nature, entering liver and spleen meridians. Has the effects of promoting qi circulation, removing blood stasis, resolving food stagnation and relieving pain. It is commonly used for blood-qi and heart pain, food stagnation, abdominal distention and pain, amenorrhea due to blood stagnation, dysmenorrhea, abdominal mass and lump, and traumatic injury. Modern researches show that the curcuma zedoary has a protective effect on both liver and kidney, and the curcuma wenyujin volatile oil has a certain anti-inflammatory effect.
The traditional Chinese medicine composition comprises raw astragalus mongholicus, codonopsis pilosula, cornus officinalis, herba lycopi, rhizoma alismatis, radix ranunculi ternati, rhizoma smilacis glabrae, caulis piperis futokadsurae, rhizoma dioscoreae nipponicae, trichosanthes kirilowii, angelica sinensis and curcuma zedoary. Wherein, the astragalus root is used as a monarch drug for tonifying qi and strengthening exterior, inducing diuresis and reducing edema, the codonopsis pilosula and the dogwood fruit are used as ministerial drugs for assisting the astragalus root to tonify kidney qi, and the herba lycopi, the rhizoma alismatis, the radix ranunculi ternate, the radix trichosanthis and the rhizoma smilacis glabrae are used as ministerial drugs. The traditional Chinese medicine composition has the advantages of complete monarch, minister, assistant and guide effects, strict compatibility and mutual assistance, has the functions of reinforcing the kidney, dispelling wind, eliminating turbidity and dredging collaterals, has very obvious clinical symptoms of improving diabetic nephropathy, can reduce blood creatinine, urea nitrogen and urine protein of diabetic nephropathy patients, has a good kidney protection effect, and has a good application prospect.
Detailed Description
The present invention is further described with reference to the following examples, which are intended to be illustrative only and not to be limiting of the scope of the claims, and other alternatives which may occur to those skilled in the art are within the scope of the claims.
Example 1: taking 5g of raw astragalus membranaceus, 20g of codonopsis pilosula, 5g of prepared cornus officinalis, 20g of herba lycopi, 5g of rhizoma alismatis, 30g of radix ranunculi ternati, 10g of rhizoma smilacis glabrae, 20g of kadsura pepper stem, 5g of dioscorea nipponica, 20g of radix trichosanthis, 5g of angelica sinensis and 20g of rhizoma zedoariae, adding water with the weight being 16 times that of medicinal materials, decocting for 1 hour, filtering, adding water with the weight being 8 times that of the medicinal materials into medicinal residues, decocting for 1 hour, combining water decoction liquid obtained in two times, filtering, concentrating the filtrate, drying in vacuum to obtain extract dry powder, adding dextrin, granulating by a wet method with 80% ethanol, and.
Example 2: taking 30g of raw astragalus membranaceus, 5g of codonopsis pilosula, 20g of prepared cornus officinalis, 5g of herba lycopi, 20g of rhizoma alismatis, 5g of radix ranunculi ternati, 40g of rhizoma smilacis glabrae, 5g of kadsura pepper stem, 20g of dioscorea nipponica, 5g of radices trichosanthis, 20g of angelica sinensis and 5g of rhizoma zedoariae, adding water with the weight being 16 times that of the raw materials, decocting for 1 hour, filtering, adding water with the weight being 8 times that of the raw materials into dregs of a decoction, decocting for 1 hour, combining water decoction solutions of the two times, filtering, concentrating the filtrate, drying in vacuum to obtain extract dry powder, adding starch.
Example 3: taking 30g of raw astragalus membranaceus, 15g of codonopsis pilosula, 10g of prepared cornus officinalis, 12g of herba lycopi, 10g of rhizoma alismatis, 30g of radix ranunculi ternati, 40g of rhizoma smilacis glabrae, 12g of kadsura pepper stem, 15g of dioscorea nipponica, 15g of radix trichosanthis, 12g of angelica sinensis and 10g of curcuma zedoary, adding water with the weight being 16 times that of the raw materials, decocting for 1 hour, filtering, adding water with the weight being 8 times that of the raw materials into medicinal residues, decocting for 1 hour, combining decoction liquid obtained in two times, filtering, concentrating the filtrate, performing spray drying to obtain extract dry powder, adding dextrin into the extract.
Example 4: taking 30g of raw astragalus membranaceus, 15g of codonopsis pilosula, 10g of prepared cornus officinalis, 12g of herba lycopi, 10g of rhizoma alismatis, 30g of radix ranunculi ternati, 40g of rhizoma smilacis glabrae, 12g of kadsura pepper stem, 15g of dioscorea nipponica, 15g of radix trichosanthis, 12g of angelica sinensis and 10g of curcuma zedoary, adding water with the weight being 16 times that of the raw materials, decocting for 1 hour, filtering, adding water with the weight being 8 times that of the raw materials into medicinal residues, decocting for 1 hour, combining water decoction of the two times, filtering, concentrating the.
Example 5: taking 30g of raw astragalus membranaceus, 15g of codonopsis pilosula, 10g of prepared cornus officinalis, 12g of herba lycopi, 10g of rhizoma alismatis, 30g of radix ranunculi ternati, 40g of rhizoma smilacis glabrae, 12g of kadsura pepper stem, 15g of dioscorea nipponica, 15g of radix trichosanthis, 12g of angelica sinensis and 10g of curcuma zedoary, adding water with the amount which is 16 times of the weight of the medicinal materials, decocting for 1 hour, filtering, adding water with the amount which is 8 times of the weight of the medicinal materials into medicinal residues, decocting for 1 hour, combining decoction liquid obtained in two times, filtering, concentrating the filtrate, spray.
Example 6: clinical observation of the invention for treating diabetic nephropathy
1. The source of the cases is: 80 diabetic nephropathy patients who are treated by special outpatient service or hospitalized in 3 months of nephrology department from 2018 to 2020 in Nanjing, the patients who are treated and enter the treatment group are all in accordance with the syndrome of kidney deficiency, dampness and turbidity and blood stasis, and the patients who are in accordance with the inclusion standard are divided into a treatment group and a control group according to a random control principle, wherein 40 patients in each group.
2. Diagnostic criteria for diabetic nephropathy: according to the diagnosis standard of diabetic nephropathy, which is issued by the endocrine society of Chinese medical society for Endocrinology 2016 (Chinese adult diabetes nephropathy clinical diagnosis specialist consensus), and improved global kidney disease prognosis organization KDIGO (CKD assessment and management clinical practice guideline 2012), the diagnosis standard belongs to stage III and stage IV DN as observation objects according to the Mogensen staging standard. The method specifically comprises the following steps: firstly, the exact history of diabetes mellitus is provided; ② fundus retinopathy; ③ the quantification of urinary microalbumin is more than 30mg/24h or the urinary albumin/urinary creatinine is more than 30 mg/mmol. And the eGFR is more than 10 ml/min.
3. The treatment grouping method comprises the following steps: before selection, the basic physical signs are stable by treatment of limiting protein intake, giving high-quality low-protein diet, controlling blood sugar, reducing blood pressure and the like, and the cases meeting the selection conditions enter the test. The selected cases were as follows 1: 1 were randomly divided into treatment and control groups. In this study, 2 patients were dropped from the treatment group, 38 patients were treated, and 40 patients were compared.
(1) Basic treatment: performing related basic knowledge propaganda and education on the patient; a low salt, low fat, high quality, low protein diet; the dosage of the oral hypoglycemic agent or insulin is determined according to specific disease conditions, so that the blood sugar reaches the standard and the occurrence of low blood sugar is avoided, the fasting blood sugar is less than or equal to 7.1mmol/L, the blood sugar after 2 hours of meal is less than 11.1mmol/L, and the glycosylated hemoglobin is less than 7 percent.
(2) Control group treatment: at the same time as the basic treatment, hypertensive patients were given irbesartan 150mg 1 time a day according to blood pressure conditions. Patients with serum creatinine >265umol/l select non-ACEI, ARB antihypertensive drugs to control blood pressure.
(3) Treatment group treatment: non-ACEI, ARB class drugs were selected for hypotension in the basal treatment. And the oral liquid prepared in example 4 was administered. The medicine is taken in the morning and evening for 2 times, 20ml each time, and the treatment course is 8 weeks.
Note: p <0.01 compared to the matched sample t test used in the group before treatment. Compared with the control group after treatment, the delta P is less than 0.05, and the delta P is less than 0.01.
Note: p <0.05, P <0.01, compared to the pretreatment pair in this group. Compared with the control group after treatment, the delta P is less than 0.05.
The above clinical applicationExperiments show that the invention can reduce Scr (mu mol/L), BUN (mmol/L), ACR (mg/gCr) and MALb (mg/L) and increase GFR (ml/min)*1.73m2) Compared with a control group, the composition has significant difference, which shows that the composition has good treatment effect on diabetic nephropathy.
Example 7: pharmacodynamic experiments of the invention
1. Apparatus and materials
1.1 Main instruments: HEA-230 glucometer (OMRON, Japan), blood glucose test paper (OMRON, Japan), 5415R type centrifuge (Eppendorf, Germany), Sartorius electronic balance (Sidoris scientific instruments (Beijing) Co., Ltd.), Hitachi OLYMPUS automated biochemical analyzer (model 7600, Nanjing Sanko Co., Ltd.).
1.2 reagent: streptozotocin (STZ, SIGMA); example 4 the resulting oral liquid formulation was prepared.
1.3 Experimental animals: 60 healthy male Sprague-Dawley (SD) rats, clean grade, 4-6 weeks old, body weight approximately 140-: SYXK (threo) 2017-0040. After the adaptive feeding is carried out for one week, the experiment is carried out without adverse reaction.
2. Experimental methods
2.1, molding: the method comprises the following steps of grouping 50 SD rats according to a random digital table, wherein 10 rats in a normal group (N group) and 50 rats in a molding group are adaptively fed for 7 days, fasting for 12 hours, weighing and preparing a diabetic nephropathy model, carrying out left-side intraperitoneal injection on the model group at one time according to 55mg/kg of a 1% Streptozotocin (STZ) solution, carrying out left-side intraperitoneal injection on the normal group (N group) by using an equivalent amount of physiological saline, carrying out standard diet on each group, periodically replacing padding and disinfecting cages. And (3) continuously measuring random blood sugar for 3 days 72 hours after the STZ solution is injected into the model, wherein the blood sugar value is more than 16.7mmol/L, the preparation of the Diabetes Mellitus (DM) model is successful, the persons who do not reach the standard are repeatedly injected into the left abdominal cavity of the STZ solution with the concentration of 55mg/kg for 1 time, and the persons who reach the standard in blood sugar are repeatedly measured after 5 days and enter the subsequent Diabetic Nephropathy (DN) model. After the rats which are successfully molded by DM are fed for 1 week, the random blood sugar is more than 16.7mmol/L, the urine volume is 1.5 times or more of that of the normal group (N group), and the 24h urine protein is 1.5 times or more of that of the normal group (N group), so that the model DN model is successfully prepared, and the molded rats which have the index which is not up to the standard are removed.
2.2 grouping and administration: 40 rats of DN model are randomly divided into 10 model groups (DN group), 10 low-dose groups of Chinese herbal compound, 10 medium-dose groups of Chinese herbal compound (GSM group) and 10 high-dose groups of Chinese herbal compound (GSH group). The dosage of the rat is calculated according to the body weight per kilogram of the animals and the human bodies (6.25 times of the human bodies), and the low, medium and high dosage groups of the traditional Chinese medicine compound group adopt the medicinal components prepared in the example 1. The group N and the group DN are administrated by 0.1ml/10g normal saline, the compound Chinese medicine components are administrated according to low, medium and high concentrations (respectively 10.99, 21.98 and 43.96g/kg) of the tested medicine respectively, the administration volume is 0.1ml/10g, the administration is carried out for 1 time every day, and the administration is carried out continuously for 6 weeks.
2.3 observation indexes: blood sugar: and detecting the random blood sugar of the rat by using an HEA-230 glucometer respectively on 0 day, 21 days and 42 days after the molding is successful. 24-hour urinary protein quantification: after the model is formed and after the medicine intervention is finished, urine is collected for 24 hours by using a metabolism cage respectively, the urine volume is recorded, and the 24-hour urine protein content is measured by a radioimmunoassay. Renal function: blood samples were collected in the clinical laboratory of Hospital, Nanjing, and Scr and BUN were detected by an OLYMPUS automatic biochemical analyzer. Observation of kidney histopathology: the rat is anesthetized, then the cervical vertebra is removed, the right kidney is taken, the capsule is removed, the kidney blood vessel is irrigated by normal saline to remove blood, the filter paper is dried, the rat is cut along the sagittal median line, 1/2 is placed into 4 percent paraformaldehyde fixing solution, the rat is embedded by normal paraffin after 48 hours, the rat is sliced by 4um continuously, the rat is stained by HE, and the pathological and histological changes of the kidney are observed under a light mirror.
2.4 statistical treatment: statistical analysis was performed using SPSS26.0 software. The measured data are expressed in terms of (X +/-S), two-by-two comparison adopts t test, and multiple groups of comparison adopts one-factor variance analysis. P <0.05 is statistically significant.
3. Results of the experiment
3.1 comparison of fasting plasma glucose in rats of each group (Table 3)
Table 3 comparison of random blood glucose changes (mmol/L) (X ± S) (n ═ 10) in each group of rats
Note: compared with normal control group, the delta P is less than 0.01, and compared with model group, the color P is less than 0.05
Compared with the normal control group, the blood sugar of the mice in the rest groups is obviously increased (P <0.01), and the blood sugar of the administration groups is not obviously different (P > 0.05). Over time, blood glucose in each administration group was reduced compared to the model group, and the difference was statistically significant (P < 0.05).
3.2 conditions of 24-hour urine protein in rats of each group (Table 4)
Table 4 comparison of 24h urine protein (mg/24h) (X ± S) (n ═ 10) for each group of rats
Note: compared with a normal control group, the delta P is less than 0.01, and compared with a model group, the quantitative rate of the urine protein of each group is improved, the decrease is most obvious in a high-dose group of the tested traditional Chinese medicine, and the # P is less than 0.01.
3.3 comparison of serum levels of Scr and BUN in rats of each group (Table 5)
Table 5 serum Scr, BUN levels (X ± S) of rats in each group (n ═ 10)
Note: in comparison with the normal group,#P<0.01, Δ P compared to model group<0.05。
3.4 pathological integral comparison of rat kidney in each group (Table 6)
Table 6 pathological integral of rat kidney (X ± S) (n ═ 10)
Note: in comparison with the set of models,ΔP<0.05。
and (4) conclusion: the invention can effectively reduce the blood sugar, blood creatinine, urea nitrogen and 24-hour urine protein of a diabetic nephropathy rat, and improve the kidney injury, and the curative effect of the invention is related to the drug dosage.
Claims (6)
1. A traditional Chinese medicine composition for treating diabetic nephropathy is characterized by being prepared from the following traditional Chinese medicines in parts by weight: 5-30 parts of raw astragalus membranaceus, 5-20 parts of codonopsis pilosula, 5-20 parts of cornus officinalis, 5-20 parts of herba lycopi, 5-20 parts of rhizoma alismatis, 5-30 parts of radix ranunculi ternati, 10-40 parts of rhizoma smilacis glabrae, 5-20 parts of kadsura pepper stem, 5-20 parts of rhizoma dioscoreae nipponicae, 5-20 parts of trichosanthes root, 5-20 parts of angelica sinensis and 5-20 parts of curcuma zedoary.
2. The traditional Chinese medicine composition as claimed in claim 1, which is prepared from the following traditional Chinese medicines in parts by weight: 15-30 parts of raw astragalus membranaceus, 10-20 parts of codonopsis pilosula, 8-20 parts of prepared cornus officinalis, 8-20 parts of herba lycopi, 5-20 parts of rhizoma alismatis, 15-30 parts of radix ranunculi ternati, 20-40 parts of rhizoma smilacis glabrae, 8-20 parts of kadsura pepper stem, 10-20 parts of rhizoma dioscoreae nipponicae, 10-20 parts of trichosanthes root, 8-20 parts of angelica sinensis and 8-20 parts of curcuma zedoary.
3. The traditional Chinese medicine composition according to claim 2, which is prepared from the following traditional Chinese medicines in parts by weight: 30 parts of raw astragalus membranaceus, 15 parts of codonopsis pilosula, 10 parts of prepared cornus officinalis, 12 parts of herba lycopi, 10 parts of rhizoma alismatis, 30 parts of radix ranunculi ternati, 40 parts of rhizoma smilacis glabrae, 12 parts of kadsura pepper stem, 15 parts of rhizoma dioscoreae nipponicae, 15 parts of trichosanthes root, 12 parts of angelica sinensis and 10 parts of curcuma zedoary.
4. The traditional Chinese medicine composition according to any one of claims 1 to 3, which is prepared by a method comprising the following steps: extracting with water, and making into final product.
5. The Chinese medicinal composition according to any one of claims 1 to 3, wherein the Chinese medicinal preparation is prepared by extracting the Chinese medicinal materials and adding pharmaceutically acceptable adjuvants, and is in the form of pill, tablet, capsule, granule, soft capsule or oral liquid.
6. The use of a Chinese medicinal composition according to any one of claims 1-3 in the preparation of a medicament for the treatment of diabetic nephropathy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110318766.4A CN112933201A (en) | 2021-03-25 | 2021-03-25 | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating diabetic nephropathy and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110318766.4A CN112933201A (en) | 2021-03-25 | 2021-03-25 | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating diabetic nephropathy and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112933201A true CN112933201A (en) | 2021-06-11 |
Family
ID=76226804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110318766.4A Pending CN112933201A (en) | 2021-03-25 | 2021-03-25 | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating diabetic nephropathy and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112933201A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115040622A (en) * | 2022-08-03 | 2022-09-13 | 南京市中医院 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101548997A (en) * | 2005-10-08 | 2009-10-07 | 河北以岭医药研究院有限公司 | Application of medicament acting on NEI network for preparing medicine for curing vas pathological changes |
-
2021
- 2021-03-25 CN CN202110318766.4A patent/CN112933201A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101548997A (en) * | 2005-10-08 | 2009-10-07 | 河北以岭医药研究院有限公司 | Application of medicament acting on NEI network for preparing medicine for curing vas pathological changes |
Non-Patent Citations (2)
Title |
---|
崔瑛等: "参芪地黄汤联合糖尿病电脑治疗仪治疗早期糖尿病肾病对照观察", 《实用中医内科杂志》 * |
施旭辉主编: "《马中夫五十年临证医鉴》", 31 March 2014, 辽宁科学技术出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115040622A (en) * | 2022-08-03 | 2022-09-13 | 南京市中医院 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
CN115040622B (en) * | 2022-08-03 | 2023-04-25 | 南京市中医院 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
CN102343023B (en) | Medicinal composition and preparation method and application thereof | |
CN104547579A (en) | Medicine composition for treating hyperprolactinemia infertility and application of medicine composition | |
CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
CN102488743B (en) | Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation | |
CN103142842B (en) | Traditional Chinese medicine for treating diabetes mellitus | |
CN102988675B (en) | Traditional Chinese medicine combination for treating chronic prostatitis and preparation method thereof | |
CN101053619B (en) | Medicine for treating pulmonary fibrosis | |
JP2002154979A (en) | Medicine composition for i type allergy and method for producing the same | |
CN101406598B (en) | Chinese medicine composite for treating diabetes and preparation method thereof | |
CN113713039A (en) | Traditional Chinese medicine composition for treating membranous nephropathy and application thereof | |
CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
CN112933201A (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating diabetic nephropathy and preparation method thereof | |
CN100522230C (en) | Medicine for treating diabetes and hephrosis and its preparing method | |
CN100518809C (en) | Medicinal composition for curing diabetes and nephropathy and its preparing method | |
CN105267559B (en) | A kind of drug and preparation method thereof for treating diabete peripheral herve pathology | |
CN114848765B (en) | Traditional Chinese medicine composition for delaying progression of chronic kidney disease and application thereof | |
CN101085121A (en) | Traditional Chinese medicine composition with hypoglycemic and antilipemic function and making method and application | |
CN102114189A (en) | Chinese medicinal blood glucose reducing tablet for treating diabetes comprising superfine powder | |
CN105999058B (en) | Bidens bipinnata lipid-lowering tablet | |
CN105327115B (en) | A kind of prevention and treatment type II diabetes Phellinus is logical to rush down formula and preparation process | |
CN107007702A (en) | A kind of Chinese medicine composition and its preparation for treating osteoarthropathy | |
CN104758705A (en) | Traditional Chinese medicine composition for treating chronic glomerulo nephritis and preparation method thereof | |
CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
CN116098958B (en) | Traditional Chinese medicine composition for treating early diabetic nephropathy with symptoms of deficiency of both qi and yin and blood stasis and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210611 |